# SOUTHWEST JOURNAL of PULMONARY & CRITICAL CARE

Journal of the Arizona, New Mexico, Colorado and California Thoracic Societies <u>www.swjpcc.com</u>

#### January 2021 Critical Care Case of the Month: Ataque Isquémico Transitorio in Spanish

Mohammad Mahmoud DO MD Bo Gu MD Benito Armenta BA Nikita Samra

Doctors Medical Center of Modesto and Emanuel Medical Center Modesto and Turlock, CA USA

#### History of Present Illness:

The patient is a previously healthy 61-yearold Spanish-speaking woman who was unable to speak after awakening. Per Emergency Medical Service she was found to be aphasic upon their arrival. While in the Emergency Room the patient was able to speak, alert and oriented x4, with all her symptoms spontaneously resolved. The patient denied fever, chills, blurred vision, headache or any history of migraines, TIA, or stroke. The patient had a similar event about two weeks earlier which also spontaneously resolved. During that time, the patient had a non-contrast CT head and an MRI of the brain, both of which were unremarkable. Her home medications include aspirin 81 mg and atorvastatin 40 mg daily.

### Past Medical History, Family History and Social History

The patient denies tobacco use or use of illicit drugs. She reports that she will occasionally drink alcohol. There is no family history of strokes.

#### **Physical Examination**

- Vitals: BP 123/80 mm Hg, T-max of 36.5° C, heart rate 72 bpm, SpO2 97%.
- HEENT: scleral icterus.
- Lungs: clear
- Heart: regular rhythm
- Abdomen: soft without organomegaly, masses or tenderness
- Skin: jaundiced
- Neurological examination:
  - Alert and oriented x4 with no focal neurological deficit observed
  - Cranial nerves II to XII were intact
  - Normal motor function
  - o Normal speech
  - No facial asymmetry or facial droop
  - o Normal mood and affect

Which of the following *laboratory tests* should be ordered?

- 1. None. She should be sent home.
- 2. Serum calcium/phosphorus

- 3. Liver function studies
- 4. 1 and 3
- 5. All of the above

#### Correct! 4. 1 and 3

Based on the initial history and physical examination, a variety of laboratory and radiologic studies are indicated. Because the physical examination shows scleral icterus and jaundice, liver function testing (lactic dehydrogenase [LDH], alanine transaminase [ALT], aspartate aminotransferase [AST], alkaline phosphatase [ALP], and bilirubin) is indicated (Table 1).

PTD 14.4	1	A 100 - 000 - 000 - 000 - 000	120022000-001
able	1 itter	tunction	tecting
Tuon	T' TULLT	runcuon	ucoung

Laboratory test	Value	Normal Range
Total bilirubin	5.8 mg/dL	0.1-1.2 mg/dL
Direct bilirubin	0.56 mg/dL	<0.3 mg/dL
LDH	405 U/L	140-280 U/L
Alanine transaminase (ALT)	7 U/L	7-55 U/L
Aspartate transaminase (AST)	24 U/L	8-48 U/L
Alkaline phosphatase (ALP)	85 U/L	40-129 U/L
Click here to display 7	Table 1 in a	<u>un enlarged</u>
window.		

There is no apparent indication for serum calcium or phosphorus at this time.

#### Based on the above, what <u>additional</u> <u>laboratory testing</u> should be obtained?

- 1. Complete blood count
- 2. Reticulocyte count
- 3. Serum haptoglobin
- 4. 1 and 3
- 5. All of the above

#### Correct! 5. All of the above

The total bilirubin is increased while the direct bilirubin is minimally elevated. Therefore, the indirect (unconjugated) must be elevated. In the absence of bruising or

bleeding into a body organ the most common cause would be hemolytic anemia (1). The elevated serum LDH is consistent with LDH released from red blood cells in a hemolytic anemia. Additional laboratory testing of a complete blood count, reticulocyte count and serum haptoglobin would confirm the diagnosis. The diagnostic work-up done while the patient was in the emergency department was showed a hemoglobin of 8.1 g/dL (normal 12.0 to 15.5 g/dL), a hematocrit of 24.1 (normal 35.5 to 44.9), a mean corpuscular volume (MCV) of 96.7, and a platelet count of  $24 \times 10^{3}$ /mcL (normal 150,000-300,000 cells/mcL). The reticulocyte was increased at 9.4% and the serum haptoglobin was decreased at <30/mg/dL consistent with haptoglobin binding to hemoglobin released during hemolysis. Prothrombin time (PT), partial thromboplastin time (PTT), creatinine and blood urea nitrogen (BUN) were all normal.

The patient was admitted with an initial diagnosis of hemolytic anemia and transient aphasia of unclear etiology.

#### What *imaging studies* should be ordered?

- 1. Brain MRI
- 2. Chest X-ray
- 3. Head CT angiography
- 4. 1 and 3
- 5. All of the above

#### Correct! 4. 1 and 3 or 5. All of the above

A chest x-ray has been shown to be of benefit only when indicated (2). In this case, it could be argued that a search for possible lung lesion which might account for the neurological findings through a metastasis is possible.

An initial CT of the head was ordered (Figure 1).



Figure 1. Initial CT of head. <u>Click here to</u> display Figure 1 in an enlarged window.

It was followed by a head CT angiogram (Figure 2).





Figure 2. CT angiogram of head. <u>Click here</u> to display Figure 2 in an enlarged window.

## What do the <u>head CT and CT angiogram</u> <u>show</u>?

- 1. The head CT angiogram is normal
- 2. The head CT angiogram shows a lesion in the lower portion of the carotid artery
- 3. The head CT is normal
- 4. 1 and 3
- 5. All of the above

#### Correct! 4. 1 and 3

Both the head CT scan and the CT angiogram were interpreted as normal. The narrowing of the left common carotid artery seen in the composite view (Figure 2C) is an artifact and not confirmed in the other view of the left common (Figure 2B).

#### Which of the following are <u>considerations in</u> <u>the differential diagnosis</u>?

- 1. Disseminated intravascular coagulation (DIC)
- 2. Immune thrombocytopenia (ITP)
- 3. Thrombotic thrombocytopenic purpura (TTP)
- 4. 1 and 3
- 5. All of the above

#### Correct! 5. All of the above

All are considerations. Their characteristics are summarized in Table 2 (3).

California C	107	170	DHC.
Palligners	Anglaster autories	Entrelient delet	Throubs: eniesi
Chesis Contena	Normal	Set	54
Mard Lodie	Normat	Stationes	Sdatuertta
FT (D30	Normal	Normal Taging surrensel	Incomed
ru	Normal	Normal Sights increased	Inspensed
Filinargen	Normal	Sighty assessed.	Depresed
Tilerio ressances	Normal	Sighty appeared	Travegaed
Filmer degradament	Normal	Sightr anyward	Increased
D domen	Normal	Highly successed	Dimension
Theore	Steroada, IV1G, apinaecturary	Planna Xilmage, resonance	Phanes, pinteiro, ATIII ()

<u>Click here to display Table 2 in an enlarged</u> <u>window</u>.

The differential diagnosis included TIA/stroke and possible TTP initially, but TTP was less likely as the patient had normal renal function with no evidence of purpura or petechiae. Additional laboratory and radiological studies were indicated to further narrow the differential diagnosis.

### Which laboratory test would <u>confirm a</u> <u>diagnosis of TTP?</u>

- 1. ADAMTS-13
- 2. Anti-thrombin 3
- 3. Bone marrow aspiration
- 4. 1 and 3
- 5. All of the above

#### Correct! 1. ADAMTS-13

A test for ADAMTS-13 was ordered with a very low level confirming TTP (4-7). ADAMTS13 is an enzyme primarily synthesized in the liver. Its main function is to cleave von Willebrand factor anchored on the endothelial surface. While the test was pending, the patient was started on corticosteroids with no significant clinical response appreciated. The diagnosis of TTP was confirmed when a very low ADAMTS-13 level was reported.

For TTP patients clinically unresponsive to corticosteroids, what <u>alternative therapies can</u> <u>be used</u>?

- 1. Plasma exchange
- 2. Rituximab
- 3. Vincristine
- 4. 1 and 3
- 5. All of the above

#### Correct! 5. All of the above

Wu et al (8) reported that ADAMTS13 response to early plasma exchange therapy in patients with acquired TTP has prognostic value. In their study of 19 patients, recovery of ADAMTS13 activity to more than 10% within 7 days was significantly associated with a timely clinical response. In contrast, patients whose ADAMTS13 level failed to exceed 10% by 7 days tended to experience TTP exacerbation, treatment refractoriness, or death.

Our patient had a dramatic clinical response to plasma exchange and Rituximab (5). She was deemed stable for discharge with Rituximab, outpatient plasmapheresis and follow up.

#### References

- Brodsky RA. Diagnosis of hemolytic anemia in adults. UpToDate. October 12, 2021. Available at: <u>https://www.uptodate.com/contents/diagnosis-of-hemolytic-anemia-in-adults</u> (accessed 12/3/21, requires subscription).
- Hubbell FA, Greenfield S, Tyler JL, Chetty K, Wyle FA. The impact of routine admission chest x-ray films on patient care. N Engl J Med. 1985 Jan 24;312(4):209-13. [CrossRef] [PubMed]
- Wun T. Thrombotic Thrombocytopenic Purpura (TTP). Medscape. May 25, 2021. Available at: <u>https://emedicine.medscape.com/article/2</u> 06598-overview (accessed 12/3/21).
- ZE, Okunji C, Hunt RC, Gupta T, Allen CE, Plum E, Blaisdell A, Grigoryan V, Geetha S, Fathke R, Soejima K, Kimchi-Sarfaty C. Characterization of conformation-sensitive antibodies to ADAMTS13, the von Willebrand cleavage protease. PLoS One. 2009 Aug 5;4(8):e6506. [CrossRef] [PubMed]
- Masias C, Vasu S, Cataland SR. None of the above: thrombotic microangiopathy beyond TTP and HUS. Blood. 2017 May 25;129(21):2857-2863. [CrossRef] [PubMed]
- Shah N, Rutherford C, Matevosyan K, Shen YM, Sarode R. Role of ADAMTS13 in the management of thrombotic microangiopathies including

thrombotic thrombocytopenic purpura (TTP). Br J Haematol. 2013 Nov;163(4):514-9. [CrossRef] [PubMed]

- Michael M, Elliott EJ, Craig JC, Ridley G, Hodson EM. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis. 2009 Feb;53(2):259-72. [CrossRef] [PubMed]
- 8. Wu N, Liu J, Yang S, Kellett ET, Cataland SR, Li H, Wu HM. Diagnostic

and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura. Transfusion. 2015 Jan;55(1):18-24. [CrossRef] [PubMed]

 Gutterman LA, Kloster B, Tsai HM. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis. 2002 May-Jun;28(3):385-91. [CrossRef] [PubMed]